lipoprotein <a>; Lp<a>
Jump to navigation
Jump to search
Function
- Lp<a> inhibits activation of plasminogen, thus inhibits fibrinolytic activity
Structure
- very similar to LDL except that its apoB100 is covalently attached via disulfide linkage to apo<a>, a large MW protein [400-800 kD] with homology to plasminogen
Expression
- synthesized in the liver
Pharmacology
- olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver[6]
More general terms
Additional terms
References
- ↑ Grainger et al Science 260:1655 1993
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
- ↑ Tietz Textbook of Clinical Chemistry, 2nd ed. Burtis CA & Ashwood ER (eds), WB Saunders Co, Philadelphia PA, 1993, pg 1023-24
- ↑ Suk Danik J et al, Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006, 296:1363 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16985228
- ↑ Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, et al, Lipoprotein(a) Levels and Risk of Future Coronary Heart Disease: Large-Scale Prospective Data. Arch Intern Med. 2008 Mar 24;168(6):598-608. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18362252
- ↑ 6.0 6.1 O'Donoghue ML, Rosenson RS, Gencer B et al Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022. Nov 6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36342163 https://www.nejm.org/doi/full/10.1056/NEJMoa2211023
- ↑ Wikipedia: Lipoprotein(a) http://en.wikipedia.org/wiki/Lipoprotein(a)